Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence

Inactivation of the E-Prostanoid 3 Receptor Attenuates the Angiotensin II Pressor Response via Decreasing Arterial Contractility

(2012) Lihong Chen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12antagonist bothin-vitroandex-vivoin human volunteers

(2012) S.C. Fox et al.   PLATELETS

Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention

(2011) Matteo Nicola Dario Di Minno et al.   ANNALS OF MEDICINE

The Perils of Combination Antithrombotic Therapy and Potential Resolutions

(2011) Marc Fisher et al.   CIRCULATION

The role of PGE2 in human atherosclerotic plaque on platelet EP3 and EP4 receptor activation and platelet function in whole blood

(2011) Lisa J. Schober et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Arterial thrombosis—insidious, unpredictable and deadly

(2011) Shaun P Jackson   NATURE MEDICINE

A Volumetric Method for Quantifying Atherosclerosis in Mice by Using MicroCT: Comparison to En Face

(2011) David J. Lloyd et al.   PLoS One

Prostaglandin E2 Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors

(2010) G. Petrucci et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Antiplatelet therapies for the treatment of cardiovascular disease

(2010) Alan D. Michelson   NATURE REVIEWS DRUG DISCOVERY

The role of prostanoid receptors in mediating the effects of PGE2on human platelet function

(2010) David Iyú et al.   PLATELETS

PGE1 and PGE2 modify platelet function through different prostanoid receptors

(2010) David Iyú et al.   PROSTAGLANDINS & OTHER LIPID MEDIATORS

The EP3-agonist sulprostone, but not prosta glandin E2 potentiates platelet aggregation in human blood

(2010) Lisa Schober et al.   THROMBOSIS AND HAEMOSTASIS

Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation

(2010) Koh-ichi Yuhki et al.   THROMBOSIS AND HAEMOSTASIS

PGE2 decreases reactivity of human platelets by activating EP2 and EP4

(2010) James P. Smith et al.   THROMBOSIS RESEARCH

Antagonists of the EP3Receptor for Prostaglandin E2Are Novel Antiplatelet Agents That Do Not Prolong Bleeding

(2009) Jasbir Singh et al.   ACS Chemical Biology

Microscopic Computed Tomography–Based Virtual Histology for Visualization and Morphometry of Atherosclerosis in Diabetic Apolipoprotein E Mutant Mice

(2009) Hernan G. Martinez et al.   CIRCULATION

Structure−Activity Relationship Studies Leading to the Identification of (2E)-3-[l-[(2,4-Dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a Potent and Selective Prostanoid EP3 Receptor Antagonist, as a Novel Antiplatelet Agent That Does Not Prolong Bleeding

(2009) Jasbir Singh et al.   JOURNAL OF MEDICINAL CHEMISTRY

Combining Antiplatelet and Anticoagulant Therapies

(2009) David R. Holmes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data

(2009) Rikke Sørensen et al.   LANCET

DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease

(2008) Stan Heptinstall et al.   PLATELETS

Experimental Model of Warfarin-Associated Intracerebral Hemorrhage

(2008) Christian Foerch et al.   STROKE